Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Figures (1-5)

Tables (1-4)

Sum=139

Publishing Process of This Article

Item

Count

Browse

Download

Sum=13

Apr 15, 2025 (publication date) through Mar 28, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Oncol. Apr 15, 2025; 17(4): 103776
Published online Apr 15, 2025. doi: 10.4251/wjgo.v17.i4.103776

Table 1 The half maximal inhibitory concentration values of 10 anticancer drugs for two cholangiocarcinoma cell lines, mean ± SD

	Cholangiocarcinoma cell line
Antitumor drugs	RBE	HuCC-T1
5-FU	4.99 ± 2.92	0.30 ± 0.24
Gemcitabine	3.15 ± 0.58	7.23 ± 3.12
Lobaplatin	0.049 ± 0.009	0.062 ± 0.006
Oxaliplatin	0.054 ± 0.028	0.076 ± 0.014
Idarubicin	0.00072 ± 0.00082	0.00023 ± 0.00005
Doxorubicin	0.35 ± 1.13	0.0015 ± 0.0005
Epirubicin	0.0055 ± 0.0075	0.0088 ± 0.0069
Irinotecan	0.50 ± 0.13	0.65 ± 0.15
Cisplatin	0.029 ± 0.007	0.030 ± 0.008
Raltitrexed

5-FU: 5-fluorouracil.

Citation: Zhao CH, Liu H, Pan T, Xiang ZW, Mu LW, Luo JY, Zhou CR, Li MA, Liu MM, Yan HZ, Huang MS. Idarubicin-transarterial chemoembolization combined with gemcitabine plus cisplatin for unresectable intrahepatic cholangiocarcinoma. World J Gastrointest Oncol 2025; 17(4): 103776
URL: https://www.wjgnet.com/1948-5204/full/v17/i4/103776.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i4.103776